CN109045260A - 一种治疗心脏衰竭的中药组合物及其制备方法 - Google Patents
一种治疗心脏衰竭的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN109045260A CN109045260A CN201811185330.7A CN201811185330A CN109045260A CN 109045260 A CN109045260 A CN 109045260A CN 201811185330 A CN201811185330 A CN 201811185330A CN 109045260 A CN109045260 A CN 109045260A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- heart failure
- portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 52
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 241000304531 Allium macrostemon Species 0.000 claims abstract description 20
- 235000006793 Artemisia stelleriana Nutrition 0.000 claims abstract description 20
- 244000252230 Artemisia stelleriana Species 0.000 claims abstract description 20
- 244000189799 Asimina triloba Species 0.000 claims abstract description 20
- 235000006264 Asimina triloba Nutrition 0.000 claims abstract description 20
- 235000009467 Carica papaya Nutrition 0.000 claims abstract description 20
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 20
- 240000005308 Juniperus chinensis Species 0.000 claims abstract description 20
- 235000004347 Perilla Nutrition 0.000 claims abstract description 20
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 20
- 235000006413 coastal sagewort Nutrition 0.000 claims abstract description 20
- 235000008397 ginger Nutrition 0.000 claims abstract description 20
- 235000019441 ethanol Nutrition 0.000 claims abstract description 16
- 240000008154 Piper betle Species 0.000 claims abstract description 12
- 235000008180 Piper betle Nutrition 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 9
- 239000008187 granular material Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 8
- 229940100688 oral solution Drugs 0.000 claims abstract description 8
- 239000006187 pill Substances 0.000 claims abstract description 8
- 238000001556 precipitation Methods 0.000 claims abstract description 8
- 238000012545 processing Methods 0.000 claims abstract description 8
- 238000000926 separation method Methods 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims abstract description 8
- 241000207929 Scutellaria Species 0.000 claims abstract description 6
- 244000273928 Zingiber officinale Species 0.000 claims abstract 5
- 244000124853 Perilla frutescens Species 0.000 claims abstract 2
- 239000006228 supernatant Substances 0.000 claims abstract 2
- 239000012530 fluid Substances 0.000 claims description 21
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 18
- 241000234314 Zingiber Species 0.000 claims description 15
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 13
- 238000002137 ultrasound extraction Methods 0.000 claims description 9
- 235000006226 Areca catechu Nutrition 0.000 claims description 8
- 244000080767 Areca catechu Species 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 7
- 229960004756 ethanol Drugs 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 abstract description 12
- 239000000243 solution Substances 0.000 abstract description 11
- 239000007901 soft capsule Substances 0.000 abstract description 7
- 238000007634 remodeling Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract description 3
- 229910001424 calcium ion Inorganic materials 0.000 abstract description 3
- 210000004413 cardiac myocyte Anatomy 0.000 abstract description 2
- 230000003834 intracellular effect Effects 0.000 abstract description 2
- 230000001766 physiological effect Effects 0.000 abstract description 2
- 239000008155 medical solution Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 10
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 8
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 8
- 229940015301 baicalein Drugs 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 235000014676 Phragmites communis Nutrition 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- 230000036770 blood supply Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000006793 arrhythmia Effects 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- -1 flavone compound Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000008065 myocardial cell damage Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000031592 cardiac muscle cell apoptotic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了一种治疗心脏衰竭的中药组合物及其制备方法,该中药组合物包括如下重量份数原料:50‑65份黄芩、15‑25份桂枝、5‑13份栝蒌、4‑10份薤白、4‑9份槟榔、5‑12份紫苏、8‑15份陈皮、5‑10份橘络、3‑8份木瓜、1‑6份生姜;其制备方法包括如下几个步骤:1)黄芩提取液的制备;2)称取桂枝、橘络、木瓜、生姜,加水提取后,加入乙醇,进行醇沉处理,分离,取上清液,浓缩;3)混合药液的制备;4)将上述步骤所得物料混合均匀,制备成口服液、颗粒剂、胶囊剂、片剂、滴丸或软胶囊;本发明所得中药组合物可减缓心肌重塑,稳定细胞内的钙离子稳态,维持心肌细胞的正常生理活动以抑制心力衰竭的发生及进展的作用。
Description
技术领域
本发明涉及临床医学技术领域,具体涉及一种治疗心脏衰竭的中药组合物及其制备方法。
背景技术
心力衰竭(heart failure)简称心衰,是指由于心脏的收缩功能和(或)舒张功能发生障碍,不能将静脉回心血量充分排出心脏,导致静脉系统血液淤积,动脉系统血液灌注不足,从而引起心脏循环障碍症候群,此种障碍症候群集中表现为肺淤血、腔静脉淤血。心力衰竭并不是一个独立的疾病,而是心脏疾病发展的终末阶段。其中绝大多数的心力衰竭都是以左心衰竭开始的,即首先表现为肺循环淤血。
心力衰竭的主要病理表现为心肌重塑,肥大和纤维化并伴有明显的收缩功能异常为主。因为其高发病率及死亡率,对全球的卫生事业提出了极大的挑战。尽管过去几十年中人们对于心衰的发病机制及其治疗方式有了一定的研究和认识,但心衰患者的临床发病率及死亡率依旧很高。因此,研究预防心衰的发生与进展以及开发新的治疗心力衰竭的药物和方法,对于降低心衰的发病率、死亡率和改善生活质量都有重要意义。
黄芩素是从多年生草本植物中药黄芩的干燥根部提取的一种黄酮类化合物。既往中医在临床上广泛用于抗炎治疗,而在近十年来国内外对其药理作用进行了较多的研究并发现其对不同因素导致的心肌细胞损伤有一定保护作用。例如:黄芩素可以通过抑制炎症反应改善内毒素血症大鼠的心肌收缩功能。黄芩素还能通过线粒体氧化信号途径减轻心肌缺血再灌注损伤和阿霉素诱导的心肌细胞损伤。同时,黄芩素还能减轻主动脉缩窄术诱导的心肌肥大和血管紧张素II诱导的心肌重塑,而心肌重塑常伴随心功能的损伤,为心力衰竭代偿期的典型特征,若不及时去除诱因,则在短期内进展为失代偿性心力衰竭。以上的研究结果提示黄芩素可能具有减轻心衰发生及进展的作用,而在心衰的发展过程中,钙离子调节蛋白功能异常是导致心衰进展的一个重要因素,是近年来对心力衰竭发展及治疗的一个热点。基于以上研究背景,本研究通过建立腹主动脉缩窄术诱导的大鼠慢性压力负荷所致心功能受损及心肌重塑模型,给予黄芩素治疗合并重组人脑利钠肽作为对照,观察心脏结构、功能变化及心肌细胞凋亡、纤维化程度与钙离子调节蛋白的变化,探讨黄芩素在心衰的延缓功能及相关生物学机制。
在中国公开的专利文件CN104922445A中公开了一种具有治疗心力衰竭作用的中药复方组合物及其制备方法与应用,它由炙黄芪30~90份,生黄芪30~90份,山茱萸12~36份,麦冬15~45份,海藻15~45份,桂枝9~27份,生蒲黄10~30份,路路通30~90份制成。该发明根据辨证论治的中医药理论,根据心力衰竭的发病机理进行中药组方筛选,提供的中药复方配比科学合理,用药严谨,临床实验结果表明,该发明提供的中药复方组合物能明显改善心衰患者的临床症状、生活质量、心功能以及脑钠肽等指标。
但现有的治疗心脏衰竭的中药组合物存在缓解心力衰竭作用不明显,保护心肌细胞作用差的缺陷。
发明内容
针对现有技术中存在的问题,本发明提供了一种治疗心脏衰竭的中药组合物及其制备方法,有效的弥补了现有技术存在的缺陷。
为实现以上目的,本发明通过以下技术方案予以实现:
一种治疗心脏衰竭的中药组合物,所述中药组合物包括如下重量份数原料:50-65份黄芩、15-25份桂枝、5-13份栝蒌、4-10份薤白、4-9份槟榔、5-12份紫苏、8-15份陈皮、5-10份橘络、3-8份木瓜、1-6份生姜。
优选的,所述中药组合物包括如下重量份数原料:55-60份黄芩、17-20份桂枝、8-10份栝蒌、6-8份薤白、5-8份槟榔、7-10份紫苏、10-13份陈皮、6-9份橘络、5-7份木瓜、2-5份生姜。
优选的,所述中药组合物包括如下重量份数原料:58份黄芩、19份桂枝、9份栝蒌、7份薤白、6份槟榔、8份紫苏、12份陈皮、8份橘络、6份木瓜、4份生姜。
治疗心脏衰竭的中药组合物的制备方法,包括如下几个步骤:
1)将黄芩粉碎,过50-60目筛得黄芩粗粉,添加一定量60%无水乙醇,混合均匀,在一定温度条件下,超声提取三次,每次15-20min,得黄芩提取液;
2)称取桂枝、橘络、木瓜、生姜,加水提取后,加入乙醇,进行醇沉处理,分离,取上清液,浓缩至粘稠膏状;
3)将栝蒌、薤白、槟榔、紫苏、陈皮按照重量份数称取,加10倍水煎煮1-3h,至水量减少为加入量的1/10-1/8,过滤,取一次药液,将一次滤渣再加4倍量的水煎煮,煎煮20-30min,过滤,取二次药液,合并两次药液,煮沸后文火煎煮一定时间;
4)将上述步骤所得物料混合均匀,制备成口服液、颗粒剂、胶囊剂、片剂、滴丸或软胶囊。
优选的,所述步骤1)中无水乙醇与黄芩粗粉的质量比为3-4:1。
优选的,所述步骤1)中超声提取温度为0-3℃。
优选的,所述步骤3)中文火煎煮时间为5-8min。
本发明的有益效果是:
黄芩素是从多年生草本植物中药黄芩的干燥根部提取的一种黄酮类化合物,可减缓心肌重塑,稳定细胞内的钙离子稳态,维持心肌细胞的正常生理活动以抑制心力衰竭的发生及进展的作用;此外,黄芩素可抑制炎症反应及心肌纤维化,减少心肌组织中细胞凋亡。
栝蒌中含有有机酸、多种蛋白质、氨基酸和无机元素等,薤白中含有有机酸、甾体皂苷、糖类和无机元素等,两者配合,通过行气祛痰的作用,可起到扩张冠状动脉血管、抑制血管收缩、改善心功能、增强心肌供血、降低血清心肌酶水平显示出较好的调节血脂心肌的保护作用。
槟榔、紫苏、陈皮配伍,可作用于胃肠平滑肌,促进胃液分泌,加速胃肠排空,改善胃肠瘀血,从而减轻心脏负荷,有效的缓解心力衰竭症状。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
一种治疗心脏衰竭的中药组合物,该中药组合物包括如下重量份数原料:50份黄芩、25份桂枝、5份栝蒌、10份薤白、4份槟榔、12份紫苏、8份陈皮、10份橘络、3份木瓜、6份生姜。
治疗心脏衰竭的中药组合物的制备方法,包括如下几个步骤:
1)将黄芩粉碎,过50目筛得黄芩粗粉,按照60%无水乙醇与黄芩粗粉的质量比为4:1添加无水乙醇,混合均匀,在0℃条件下,超声提取三次,每次20min,得黄芩提取液;
2)称取桂枝、橘络、木瓜、生姜,加水提取后,加入乙醇,进行醇沉处理,分离,取上清液,浓缩至粘稠膏状;
3)将栝蒌、薤白、槟榔、紫苏、陈皮按照重量份数称取,加10倍水煎煮1h,至水量减少为加入量的1/8,过滤,取一次药液,将一次滤渣再加4倍量的水煎煮,煎煮20min,过滤,取二次药液,合并两次药液,煮沸后文火煎煮8min;
4)将上述步骤所得物料混合均匀,制备成口服液、颗粒剂、胶囊剂、片剂、滴丸或软胶囊。
实施例2:
一种治疗心脏衰竭的中药组合物,该中药组合物包括如下重量份数原料:65份黄芩、15份桂枝、13份栝蒌、4份薤白、9份槟榔、5份紫苏、15份陈皮、5份橘络、8份木瓜、1份生姜。
治疗心脏衰竭的中药组合物的制备方法,包括如下几个步骤:
1)将黄芩粉碎,过60目筛得黄芩粗粉,按照60%无水乙醇与黄芩粗粉的质量比为3:1添加无水乙醇,混合均匀,在3℃条件下,超声提取三次,每次15min,得黄芩提取液;
2)称取桂枝、橘络、木瓜、生姜,加水提取后,加入乙醇,进行醇沉处理,分离,取上清液,浓缩至粘稠膏状;
3)将栝蒌、薤白、槟榔、紫苏、陈皮按照重量份数称取,加10倍水煎煮3h,至水量减少为加入量的1/10,过滤,取一次药液,将一次滤渣再加4倍量的水煎煮,煎煮30min,过滤,取二次药液,合并两次药液,煮沸后文火煎煮5min;
4)将上述步骤所得物料混合均匀,制备成口服液、颗粒剂、胶囊剂、片剂、滴丸或软胶囊。
实施例3:
一种治疗心脏衰竭的中药组合物,该中药组合物包括如下重量份数原料:55份黄芩、17份桂枝、10份栝蒌、8份薤白、5份槟榔、7份紫苏、13份陈皮、9份橘络、5份木瓜、2份生姜。
治疗心脏衰竭的中药组合物的制备方法,包括如下几个步骤:
1)将黄芩粉碎,过60目筛得黄芩粗粉,按照60%无水乙醇与黄芩粗粉的质量比为4:1添加无水乙醇,混合均匀,在0℃条件下,超声提取三次,每次15min,得黄芩提取液;
2)称取桂枝、橘络、木瓜、生姜,加水提取后,加入乙醇,进行醇沉处理,分离,取上清液,浓缩至粘稠膏状;
3)将栝蒌、薤白、槟榔、紫苏、陈皮按照重量份数称取,加10倍水煎煮3h,至水量减少为加入量的1/8,过滤,取一次药液,将一次滤渣再加4倍量的水煎煮,煎煮20min,过滤,取二次药液,合并两次药液,煮沸后文火煎煮5min;
4)将上述步骤所得物料混合均匀,制备成口服液、颗粒剂、胶囊剂、片剂、滴丸或软胶囊。
实施例4:
一种治疗心脏衰竭的中药组合物,该中药组合物包括如下重量份数原料:60份黄芩、20份桂枝、8份栝蒌、6份薤白、8份槟榔、10份紫苏、10份陈皮、6份橘络、7份木瓜、5份生姜。
治疗心脏衰竭的中药组合物的制备方法,包括如下几个步骤:
1)将黄芩粉碎,过50目筛得黄芩粗粉,按照60%无水乙醇与黄芩粗粉的质量比为3:1添加无水乙醇,混合均匀,在3℃条件下,超声提取三次,每次20min,得黄芩提取液;
2)称取桂枝、橘络、木瓜、生姜,加水提取后,加入乙醇,进行醇沉处理,分离,取上清液,浓缩至粘稠膏状;
3)将栝蒌、薤白、槟榔、紫苏、陈皮按照重量份数称取,加10倍水煎煮1h,至水量减少为加入量的1/10,过滤,取一次药液,将一次滤渣再加4倍量的水煎煮,煎煮30min,过滤,取二次药液,合并两次药液,煮沸后文火煎煮8min;
4)将上述步骤所得物料混合均匀,制备成口服液、颗粒剂、胶囊剂、片剂、滴丸或软胶囊。
实施例5:
一种治疗心脏衰竭的中药组合物,该中药组合物包括如下重量份数原料:58份黄芩、19份桂枝、9份栝蒌、7份薤白、6份槟榔、8份紫苏、12份陈皮、8份橘络、6份木瓜、4份生姜。
治疗心脏衰竭的中药组合物的制备方法,包括如下几个步骤:
1)将黄芩粉碎,过55目筛得黄芩粗粉,按照60%无水乙醇与黄芩粗粉的质量比为3:1添加无水乙醇,混合均匀,在0℃条件下,超声提取三次,每次15min,得黄芩提取液;
2)称取桂枝、橘络、木瓜、生姜,加水提取后,加入乙醇,进行醇沉处理,分离,取上清液,浓缩至粘稠膏状;
3)将栝蒌、薤白、槟榔、紫苏、陈皮按照重量份数称取,加10倍水煎煮2h,至水量减少为加入量的1/9,过滤,取一次药液,将一次滤渣再加4倍量的水煎煮,煎煮25min,过滤,取二次药液,合并两次药液,煮沸后文火煎煮5min;
4)将上述步骤所得物料混合均匀,制备成口服液、颗粒剂、胶囊剂、片剂、滴丸或软胶囊。
将实施例1-5所得治疗心脏衰竭的中药组合物与现有技术中已有的治疗心脏衰竭的中药进行治疗测试:每组患者均为50名,早晚各服用一次,每组服药量均相同,连续服用4周为1个疗程,每2周记录一次,观察10疗程,结果如表1:
表1
典型病例:
张某,女,50岁,冠心病病史2年,心悸、心绞痛、房颤,心电图:心肌供血不足,房颤。连续服用实施例1所得药物10个疗程,早晚各服用一次;心率失常降低,症状明显缓解。
李某,男,48岁,有冠心病病史,心悸、心律不齐、心绞痛,心电图:心肌供血不足,室性早搏。连续服用实施例2所得药物9个疗程,早晚各服用一次;心率失常降低,症状减轻。
王某,女,51岁,有冠心病病史1年,曾因心肌梗死住院治疗,出院后仍有胸闷、气短、乏力等心肌损伤体征。连续服用实施例3所得药物9个疗程,早晚各服用一次;心脏超声显示左室收缩功能正常,无胸闷、气短体征。
鲁某,男,50岁,冠心病病史2年,伴有心绞痛、高血压,有发烧症状,体温正常后仍有心悸,前区不适,身体乏力。连续服用实施例4所得药物10个疗程,早晚各服用一次;心率失常降低,症状明显缓解。
郑某,女,49岁,冠心病病史2年,伴有心绞痛、高血压,心电图:心肌供血不足,房颤。连续服用实施例5所得药物9个疗程,早晚各服用一次;心率失常降低,症状明显缓解。
陈某,女,50岁,冠心病病史2年,伴有心绞痛、高血压,心电图:心肌供血不足,房颤。连续服用现有治疗心脏衰竭药物10个疗程,早晚各服用一次;心率失常未有明显好转,伴有胸闷、乏力等体征。
以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (7)
1.一种治疗心脏衰竭的中药组合物,其特征在于,所述中药组合物包括如下重量份数原料:50-65份黄芩、15-25份桂枝、5-13份栝蒌、4-10份薤白、4-9份槟榔、5-12份紫苏、8-15份陈皮、5-10份橘络、3-8份木瓜、1-6份生姜。
2.根据权利要求1所述的治疗心脏衰竭的中药组合物,其特征在于,所述中药组合物包括如下重量份数原料:55-60份黄芩、17-20份桂枝、8-10份栝蒌、6-8份薤白、5-8份槟榔、7-10份紫苏、10-13份陈皮、6-9份橘络、5-7份木瓜、2-5份生姜。
3.根据权利要求2所述的治疗心脏衰竭的中药组合物,其特征在于,所述中药组合物包括如下重量份数原料:58份黄芩、19份桂枝、9份栝蒌、7份薤白、6份槟榔、8份紫苏、12份陈皮、8份橘络、6份木瓜、4份生姜。
4.根据权利要求1-3的任一所述的治疗心脏衰竭的中药组合物的制备方法,其特征在于,包括如下几个步骤:
1)将黄芩粉碎,过50-60目筛得黄芩粗粉,添加一定量60%无水乙醇,混合均匀,在一定温度条件下,超声提取三次,每次15-20min,得黄芩提取液;
2)称取桂枝、橘络、木瓜、生姜,加水提取后,加入乙醇,进行醇沉处理,分离,取上清液,浓缩至粘稠膏状;
3)将栝蒌、薤白、槟榔、紫苏、陈皮按照重量份数称取,加10倍水煎煮1-3h,至水量减少为加入量的1/10-1/8,过滤,取一次药液,将一次滤渣再加4倍量的水煎煮,煎煮20-30min,过滤,取二次药液,合并两次药液,煮沸后文火煎煮一定时间;
4)将上述步骤所得物料混合均匀,制备成口服液、颗粒剂、胶囊剂、片剂、滴丸或软胶囊。
5.根据权利要求4所述的治疗心脏衰竭的中药组合物的制备方法,其特征在于,所述步骤1)中无水乙醇与黄芩粗粉的质量比为3-4:1。
6.根据权利要求4所述的治疗心脏衰竭的中药组合物的制备方法,其特征在于,所述步骤1)中超声提取温度为0-3℃。
7.根据权利要求4所述的治疗心脏衰竭的中药组合物的制备方法,其特征在于,所述步骤3)中文火煎煮时间为5-8min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811185330.7A CN109045260A (zh) | 2018-10-11 | 2018-10-11 | 一种治疗心脏衰竭的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811185330.7A CN109045260A (zh) | 2018-10-11 | 2018-10-11 | 一种治疗心脏衰竭的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109045260A true CN109045260A (zh) | 2018-12-21 |
Family
ID=64764691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811185330.7A Pending CN109045260A (zh) | 2018-10-11 | 2018-10-11 | 一种治疗心脏衰竭的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109045260A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017181987A1 (zh) * | 2016-04-21 | 2017-10-26 | 张东 | 一种对多种症状具有功效的中药组合物及其衍生物和制品 |
CN107998259A (zh) * | 2017-09-28 | 2018-05-08 | 都全荣 | 一种治疗心衰的中药配方及其制备方法 |
-
2018
- 2018-10-11 CN CN201811185330.7A patent/CN109045260A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017181987A1 (zh) * | 2016-04-21 | 2017-10-26 | 张东 | 一种对多种症状具有功效的中药组合物及其衍生物和制品 |
CN107998259A (zh) * | 2017-09-28 | 2018-05-08 | 都全荣 | 一种治疗心衰的中药配方及其制备方法 |
Non-Patent Citations (3)
Title |
---|
李七一: "《中医老年病学》", 30 September 2009, 中国中医药出版社 * |
滕训辉等: "《黄芩生产加工适宜技术》", 30 November 2017, 中国医药科技出版社 * |
陈川等: "《中医名方临床集验》", 31 January 2017, 上海科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104256008A (zh) | 山楂决明子茶及其制备方法 | |
CN102940801A (zh) | 一种治疗高血压的中药组合物 | |
CN104013849A (zh) | 一种治疗高血压病的中药组合物及其制备方法 | |
CN106421359A (zh) | 一种全面治疗糖尿病及其并发症的药物组合物 | |
CN101755970A (zh) | 一种降血压保健茶 | |
CN103989970B (zh) | 一种治疗高血压的中药组合物 | |
CN104531476B (zh) | 雪菊保健酒及其制作方法 | |
CN103751450B (zh) | 一种治疗糖尿病肾病的组合物 | |
CN109045260A (zh) | 一种治疗心脏衰竭的中药组合物及其制备方法 | |
CN105056192A (zh) | 一种治疗心肌梗死的中药组合物及其应用 | |
CN101152223A (zh) | 杨树叶酚类提取物在治疗心血管疾病中的用途及其提取方法 | |
KR102198434B1 (ko) | 천연식물을 이용한 고지혈증 예방 또는 치료용 약학 조성물, 그 제조방법 및 제제 | |
CN104027525A (zh) | 一种治疗缺血性心脏病的药物及其制备方法和其用途 | |
CN103316217B (zh) | 一种治疗心脏病的中药制剂及其制备方法 | |
CN113144076A (zh) | 一种治疗心肌炎的中药组合物 | |
CN110787273A (zh) | 一种调节尿酸的中药组合物及其应用 | |
CN100574799C (zh) | 人参四逆注射剂及制备方法 | |
CN100384442C (zh) | 一种中草药制剂及其制备方法和应用 | |
CN106138494B (zh) | 一种养肾组合物及其生产方法 | |
CN108743885A (zh) | 一种治疗糖尿病大血管病变的中药及其制备方法 | |
CN107184812A (zh) | 一种排毒补肾利湿治痛风的中药组方及其制剂 | |
CN115192657B (zh) | 一种用于治疗2型糖尿病肾脏病的中药制剂及其应用 | |
CN117244021B (zh) | 一种降血糖、血脂、血压、尿酸的中药组合提取物及其制备方法 | |
CN101468144B (zh) | 一种治疗室性早搏的中药复方制剂 | |
TWI384994B (zh) | 調節血壓之醫藥組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181221 |
|
RJ01 | Rejection of invention patent application after publication |